Biomaterials legislation
This article was originally published in The Gray Sheet
Executive Summary
The House likely will take up the "Biomaterials Access Assurance Act" (HR 872) under a suspension of the rules on July 27, House staffers say. Passage of the bill, which contains liability protections for biomaterials suppliers whose products are included in medical devices, could revive the issue in the Senate, where a broader product liability compromise containing biomaterials provisions nearly identical to the House bill was defeated July 9 ("The Gray Sheet" July 13, p. 5)